Home ETF List About

Portfolio Holdings Detail for ISIN IE00BYXG2H39
Stock Name / FundiShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerBTEC(USD) LSE
ETF TickerBTEK(GBP) LSE
ETF Ticker2B70(EUR) F
ETF Ticker2B70.DE(EUR) CXE
ETF TickerBTEC.LS(USD) CXE
ETF TickerBTEK.LS(GBP) CXE
ETF TickerBTEC.L(GBP) LSE
ETF TickerBTEK.L(GBP) LSE

Holdings detail for SYRE

Stock NameSpyre Therapeutics Inc.
TickerSYRE(USD) NASDAQ
TYPECommon Stock
CountryUSA

Show aggregate SYRE holdings

News associated with SYRE

Spyre Therapeutics (NASDAQ:SYRE) Upgraded by Wall Street Zen to “Hold” Rating
Wall Street Zen upgraded shares of Spyre Therapeutics (NASDAQ:SYRE – Free Report) from a sell rating to a hold rating in a research report sent to investors on Monday. Separately, Wedbush reiterated an “outperform” rating and issued a $65.00 price target on shares of Spyre Therapeutics in a research note on Wednesday, August 6th. Two […] - 2025-09-09 02:57:04
Brokerages Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) Price Target at $53.40
Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) has been given a consensus recommendation of “Buy” by the seven analysts that are currently covering the firm, Marketbeat reports. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 12-month target price […] - 2025-09-08 02:32:51
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives $53.40 Average PT from Analysts
Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) has been given an average recommendation of “Buy” by the seven research firms that are covering the firm, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1 year […] - 2025-08-14 02:31:05
XTX Topco Ltd Acquires Shares of 28,499 Spyre Therapeutics, Inc. (NASDAQ:SYRE)
XTX Topco Ltd acquired a new stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) in the first quarter, Holdings Channel reports. The institutional investor acquired 28,499 shares of the company’s stock, valued at approximately $460,000. A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the […] - 2025-08-08 04:38:55
The Math Shows SCHA Can Go To $31
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-08-07 09:07:38
Victory Capital Management Inc. Lowers Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE)
Victory Capital Management Inc. decreased its holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) by 6.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 251,846 shares of the company’s stock after selling 16,230 shares during the quarter. Victory Capital Management Inc.’s […] - 2025-07-28 05:02:49
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Recommendation of “Buy” by Analysts
Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) has earned an average rating of “Buy” from the seven ratings firms that are currently covering the company, Marketbeat Ratings reports. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 12 month price […] - 2025-07-17 05:10:58
122,153 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Acquired by Universal Beteiligungs und Servicegesellschaft mbH
Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 122,153 shares of the company’s stock, valued at approximately $2,844,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.24% […] - 2025-06-03 05:35:02
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Acquired by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) by 4.2% in the fourth quarter, HoldingsChannel.com reports. The firm owned 22,741 shares of the company’s stock after acquiring an additional 916 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.’s holdings in Spyre Therapeutics […] - 2025-05-30 04:48:57
Analysts Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) PT at $49.57
Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) have been assigned a consensus recommendation of “Buy” from the ten brokerages that are presently covering the stock, Marketbeat Ratings reports. Eight research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average […] - 2025-05-06 02:32:52
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Acquired by Barclays PLC
Barclays PLC lifted its position in Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) by 16.7% in the fourth quarter, Holdings Channel reports. The firm owned 123,071 shares of the company’s stock after acquiring an additional 17,604 shares during the period. Barclays PLC’s holdings in Spyre Therapeutics were worth $2,866,000 as of its most recent filing […] - 2025-04-30 05:15:05
Legal & General Group Plc Has $873,000 Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)
Legal & General Group Plc grew its holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) by 14.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 37,490 shares of the company’s stock after purchasing an additional 4,824 shares during the quarter. […] - 2025-04-28 04:56:53
Vanguard Group Inc. Purchases 330,553 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)
Vanguard Group Inc. increased its position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) by 13.1% in the 4th quarter, HoldingsChannel reports. The fund owned 2,846,473 shares of the company’s stock after acquiring an additional 330,553 shares during the period. Vanguard Group Inc. owned approximately 0.06% of Spyre Therapeutics worth $66,266,000 as of […] - 2025-04-11 05:40:57
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives $50.33 Average Price Target from Brokerages
Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) have received an average rating of “Buy” from the ten analysts that are covering the stock, Marketbeat.com reports. Eight analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month target price […] - 2025-04-11 02:54:51
Corebridge Financial Inc. Sells 1,299 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)
Corebridge Financial Inc. lowered its stake in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) by 7.0% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 17,213 shares of the company’s stock after selling 1,299 shares during the period. Corebridge Financial Inc.’s holdings in Spyre Therapeutics […] - 2025-04-10 04:49:04
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Acquired by Wellington Management Group LLP
Wellington Management Group LLP increased its position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) by 6.5% during the fourth quarter, Holdings Channel.com reports. The fund owned 1,604,508 shares of the company’s stock after acquiring an additional 97,308 shares during the quarter. Wellington Management Group LLP’s holdings in Spyre Therapeutics were worth $37,353,000 […] - 2025-04-07 06:35:09
Schroder Investment Management Group Takes $2.56 Million Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)
Schroder Investment Management Group bought a new position in Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 113,620 shares of the company’s stock, valued at approximately $2,561,000. Schroder Investment Management Group owned about 0.22% of Spyre […] - 2025-04-07 05:10:58
Natixis Advisors LLC Invests $403,000 in Spyre Therapeutics, Inc. (NASDAQ:SYRE)
Natixis Advisors LLC bought a new position in Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) during the fourth quarter, Holdings Channel reports. The firm bought 17,300 shares of the company’s stock, valued at approximately $403,000. Several other large investors have also added to or reduced their stakes in SYRE. Barclays PLC increased its holdings in […] - 2025-03-28 06:04:54
Wolfe Research Initiates Coverage on Spyre Therapeutics (NASDAQ:SYRE)
Wolfe Research assumed coverage on shares of Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) in a research report issued on Tuesday, Marketbeat.com reports. The brokerage set an “outperform” rating and a $27.00 price target on the stock. Wolfe Research’s price objective suggests a potential upside of 46.74% from the company’s previous close. Several other equities […] - 2025-03-20 04:22:57
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Average Rating of “Buy” from Analysts
Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) has been assigned a consensus recommendation of “Buy” from the eight ratings firms that are presently covering the firm, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average […] - 2025-03-14 04:25:02

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) SYRE holdings

DateNumber of SYRE Shares HeldBase Market Value of SYRE SharesLocal Market Value of SYRE SharesChange in SYRE Shares HeldChange in SYRE Base ValueCurrent Price per SYRE Share HeldPrevious Price per SYRE Share Held
2025-11-11 (Tuesday)38,586USD 900,983USD 900,983
2025-11-10 (Monday)38,586SYRE holding increased by 99USD 855,837SYRE holding decreased by -10890USD 855,83799USD -10,890 USD 22.18 USD 22.52
2025-11-07 (Friday)38,487USD 866,727SYRE holding increased by 5003USD 866,7270USD 5,003 USD 22.52 USD 22.39
2025-11-06 (Thursday)38,487SYRE holding increased by 99USD 861,724SYRE holding decreased by -15442USD 861,72499USD -15,442 USD 22.39 USD 22.85
2025-11-05 (Wednesday)38,388USD 877,166SYRE holding decreased by -4990USD 877,1660USD -4,990 USD 22.85 USD 22.98
2025-11-04 (Tuesday)38,388SYRE holding increased by 99USD 882,156SYRE holding decreased by -28356USD 882,15699USD -28,356 USD 22.98 USD 23.78
2025-11-03 (Monday)38,289USD 910,512SYRE holding decreased by -26037USD 910,5120USD -26,037 USD 23.78 USD 24.46
2025-10-31 (Friday)38,289USD 936,549SYRE holding increased by 7658USD 936,5490USD 7,658 USD 24.46 USD 24.26
2025-10-30 (Thursday)38,289SYRE holding increased by 495USD 928,891SYRE holding increased by 28260USD 928,891495USD 28,260 USD 24.26 USD 23.83
2025-10-29 (Wednesday)37,794SYRE holding increased by 198USD 900,631SYRE holding decreased by -25734USD 900,631198USD -25,734 USD 23.83 USD 24.64
2025-10-28 (Tuesday)37,596USD 926,365SYRE holding increased by 2631USD 926,3650USD 2,631 USD 24.64 USD 24.57
2025-10-27 (Monday)37,596USD 923,734SYRE holding increased by 45115USD 923,7340USD 45,115 USD 24.57 USD 23.37
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of SYRE by Blackrock for IE00BYXG2H39

Show aggregate share trades of SYRE

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-11-10BUY99 22.180* 17.71
2025-11-06BUY99 22.390* 17.65
2025-11-04BUY99 22.980* 17.58
2025-10-30BUY49524.68023.780 23.870USD 11,816 17.46
2025-10-29BUY19823.83025.005 24.887USD 4,928 17.41
2025-10-22SELL-39622.21023.398 23.279USD -9,219 17.21 Loss of -2,402 on sale
2025-10-20BUY19823.49023.530 23.526USD 4,658 17.13
2025-10-17BUY49522.47022.979 22.928USD 11,349 17.09
2025-10-15BUY79222.19022.305 22.294USD 17,656 17.06
2025-10-03BUY70015.89016.300 16.259USD 11,381 17.04
2025-10-02BUY10015.98016.700 16.628USD 1,663 17.05
2025-09-30BUY20016.76016.790 16.787USD 3,357 17.05
2025-09-26BUY20016.24016.730 16.681USD 3,336 17.06
2025-09-25BUY20015.61017.000 16.861USD 3,372 17.07
2025-09-24SELL-1,94717.00017.120 17.108USD -33,309 17.08 Loss of -64 on sale
2025-09-18BUY10615.32015.620 15.590USD 1,653 17.09
2025-09-17BUY32115.05015.350 15.320USD 4,918 17.10
2025-08-20SELL-42016.35016.530 16.512USD -6,935 17.13 Profit of 261 on sale
2025-07-30BUY42017.29017.700 17.659USD 7,417 17.15
2025-07-17SELL-21016.89016.895 16.895USD -3,548 17.16 Profit of 57 on sale
2025-07-11SELL-84015.69015.960 15.933USD -13,384 17.21 Profit of 1,072 on sale
2025-07-07BUY31515.30015.840 15.786USD 4,973 17.26
2025-07-02BUY5,77515.50016.610 16.499USD 95,282 17.29
2025-06-20BUY1,74415.01015.275 15.248USD 26,593 17.31
2025-06-11BUY20018.00019.200 19.080USD 3,816 17.37
2025-06-10BUY20018.56018.830 18.803USD 3,761 17.36
2025-06-04SELL-10016.52017.110 17.051USD -1,705 17.38 Profit of 33 on sale
2025-04-23BUY10014.22014.790 14.733USD 1,473 18.65
2025-04-10SELL-80011.93012.945 12.843USD -10,275 19.62 Profit of 5,425 on sale
2025-04-08SELL-10011.80013.280 13.132USD -1,313 19.90 Profit of 676 on sale
2025-04-07SELL-10012.39013.230 13.146USD -1,315 20.04 Profit of 690 on sale
2025-04-04SELL-50012.79013.630 13.546USD -6,773 20.19 Profit of 3,321 on sale
2025-04-01BUY40815.29516.120 16.038USD 6,543 20.39
2025-03-31SELL-30016.13517.675 17.521USD -5,256 20.48 Profit of 887 on sale
2025-03-21BUY2,05418.17018.540 18.503USD 38,005 20.84
2025-03-14SELL-1,50418.04018.985 18.891USD -28,411 21.21 Profit of 3,482 on sale
2025-03-07SELL-18619.49021.030 20.876USD -3,883 21.61 Profit of 136 on sale
2025-03-04SELL-9318.22018.590 18.553USD -1,725 21.84 Profit of 306 on sale
2025-02-25BUY18620.65021.500 21.415USD 3,983 22.43
2025-02-19SELL-9322.37022.550 22.532USD -2,095 22.56 Profit of 2 on sale
2025-02-13BUY27622.68023.750 23.643USD 6,525 22.53
2025-02-12BUY9323.27023.350 23.342USD 2,171 22.48
2025-02-11BUY37222.15022.750 22.690USD 8,441 22.51
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of SYRE

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19150,5490167,62689.8%
2025-09-18178,64830220,25281.1%
2025-09-17159,1190352,78345.1%
2025-09-16184,7030266,49769.3%
2025-09-15299,4800417,88671.7%
2025-09-1281,49051168,74648.3%
2025-09-11112,7770279,76440.3%
2025-09-1054,522089,09161.2%
2025-09-0937,286066,99655.7%
2025-09-0861,946079,86577.6%
2025-09-0567,335081,17383.0%
2025-09-0496,0610191,41850.2%
2025-09-0369,863085,04882.1%
2025-09-0270,994262126,48756.1%
2025-08-2990,1750133,87767.4%
2025-08-2841,761083,86149.8%
2025-08-2798,551830114,39486.2%
2025-08-2686,505200129,15167.0%
2025-08-2581,3540129,79162.7%
2025-08-22128,3061,294195,18665.7%
2025-08-21177,0990235,89975.1%
2025-08-20292,17563329,03088.8%
2025-08-19194,1230236,21182.2%
2025-08-18135,9750161,81484.0%
2025-08-1564,986076,34785.1%
2025-08-1448,287068,69270.3%
2025-08-1390,6630110,58882.0%
2025-08-1247,2591158,73680.5%
2025-08-11125,5930144,62686.8%
2025-08-0874,973891,13682.3%
2025-08-07101,5360117,09486.7%
2025-08-06128,728120167,97576.6%
2025-08-0580,5740108,62874.2%
2025-08-0486,9960218,52439.8%
2025-08-01107,0590187,16157.2%
2025-07-31111,3235128,33786.7%
2025-07-30311,50616340,84091.4%
2025-07-2986,541099,79786.7%
2025-07-28112,4697156,41971.9%
2025-07-25198,18218543,01236.5%
2025-07-24106,594118290,77436.7%
2025-07-23117,0570135,18586.6%
2025-07-2286,970560141,88061.3%
2025-07-2198,6090111,72088.3%
2025-07-18100,1060106,28694.2%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.